Source: Health Products Regulatory Authority (IE) Revision Year: 2023 Publisher: Cipla Europe NV, De Keyserlei 58-60, Box-19, 2018 Antwerp, Belgium
Arquist 125 microgram per actuation pressurised inhalation, suspension.
| Pharmaceutical Form |
|---|
|
Pressurised inhalation suspension (pressurised inhalation). Arquist is a white homogeneous suspension, filled in an aluminum container fitted with a suitable metering valve and a plastic actuator. White coloured body with yellow cap. |
One metered dose (ex-valve) contains 125 micrograms of fluticasone propionate. This is equivalent to a delivered dose (ex-actuator) of 110 micrograms fluticasone propionate.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Fluticasone |
Fluticasone has anti-inflammatory and vasoconstrictive features. Fluticasone given by inhalation at recommended doses has a potent glucocorticoid anti-inflammatory action within the lungs, resulting in a reduction of both symptoms and exacerbations of asthma, with a lower incidence and severity of adverse effects than those observed when corticosteroids are administered systemically. |
| List of Excipients |
|---|
|
Norflurane (HFA 134a) |
An inhaler comprising an aluminium alloy canister sealed with a metering valve, actuator and cap. Each canister contains 120 metered actuations.
Pack sizes: 1 or 2 canisters. Each canister contains 120 metered actuations.
Not all pack sizes may be marketed.
Cipla Europe NV, De Keyserlei 58-60, Box-19, 2018 Antwerp, Belgium
PA1963/012/001
Date of first authorisation: 2nd October 2015
Date of last renewal: 17th July 2019
| Drug | Countries | |
|---|---|---|
| ARQUIST | Croatia, Ireland, Romania |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
